Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. - Wikidata - wikimedia - TriplyDB

Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer.

Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer.

http://www.wikidata.org/entity/Q34601123

about

Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial Therapeutic usefulness of postoperative adjuvant chemotherapy with Tegafur-Uracil (UFT) in patients with breast cancer: focus on the results of clinical studies in Japan Latent bone metastasis in breast cancer tied to Src-dependent survival signals Identifying patients at high risk of breast cancer recurrence: strategies to improve patient outcomes Early-Stage Breast Cancer in the Elderly: Confronting an Old Clinical Problem The p53-estrogen receptor loop in cancer Phase II trial of tipifarnib plus neoadjuvant doxorubicin-cyclophosphamide in patients with clinical stage IIB-IIIC breast cancer Fifteen-year median follow-up results after neoadjuvant doxorubicin, followed by mastectomy, followed by adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) followed by radiation for stage III breast cancer: a phase II trial (CALGB 8944)Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer The prolyl isomerase Pin1 acts synergistically with CDK2 to regulate the basal activity of estrogen receptor α in breast cancer A mechanistic study of the effect of doxorubicin/adriamycin on the estrogen response in a breast cancer model Pure mucinous carcinoma of the breast: clinicopathologic characteristics and long-term outcome among Taiwanese women.Using clinical trial data to tailor adjuvant treatments for individual patients.Non-anthracycline-containing docetaxel and cyclophosphamide regimen is associated with sustained worse outcome compared with docetaxel, anthracycline and cyclophosphamide in neoadjuvant treatment of triple negative and HER2-positive breast cancer pa Building pathway clusters from Random Forests classification using class votes Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40 The potential biomarkers in predicting pathologic response of breast cancer to three different chemotherapy regimens: a case control study.Adjuvant treatment recommendations for patients with ER-positive/HER2-negative early breast cancer by Swiss tumor boards using the 21-gene recurrence score (SAKK 26/10).Myeloperoxidase genotypes and enhanced efficacy of chemotherapy for early-stage breast cancer in SWOG-8897 TP53-based interaction analysis identifies cis-eQTL variants for TP53BP2, FBXO28, and FAM53A that associate with survival and treatment outcome in breast cancer Prognostic significance of subtype classification for short- and long-term survival in breast cancer: survival time holds the key.Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies Estrogen signaling and the DNA damage response in hormone dependent breast cancers.Resistance to Taxanes in Triple-Negative Breast Cancer Associates with the Dynamics of a CD49f+ Tumor-Initiating Population.Clinical use of the Oncotype DX genomic test to guide treatment decisions for patients with invasive breast cancer.Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease.Estradiol induces export of sphingosine 1-phosphate from breast cancer cells via ABCC1 and ABCG2.PAM50 gene signatures and breast cancer prognosis with adjuvant anthracycline- and taxane-based chemotherapy: correlative analysis of C9741 (Alliance).Triple-negative breast cancer: role of specific chemotherapy agents Akt phosphorylation at Ser473 predicts benefit of paclitaxel chemotherapy in node-positive breast cancer.Adjuvant chemotherapy in breast cancer: To use or not to use, the anthracyclines Measuring decision quality: psychometric evaluation of a new instrument for breast cancer chemotherapy.Genomic index of sensitivity to endocrine therapy for breast cancer.Difference between Luminal A and Luminal B Subtypes According to Ki-67, Tumor Size, and Progesterone Receptor Negativity Providing Prognostic Information.TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial.Neoadjuvant endocrine therapy in primary breast cancer: indications and use as a research tool.Is Chemoendocrine Treatment without Alternative?Dose-Dense Chemotherapy: Principles, Clinical Results and Future Perspectives.Classical cyclophosphamide, methotrexate, and fluorouracil chemotherapy is more effective in triple-negative, node-negative breast cancer: results from two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer.Value of TP53 status for predicting response to neoadjuvant chemotherapy in breast cancer: a meta-analysis.

P2860

Q24597456-17D82195-46EC-4414-B806-DD0EEBE0A64F Q24633384-E188A5ED-5D24-4FAE-A103-769CA107DFD3 Q24648828-6F0145C8-67B2-4ADB-AAE1-E7B9ED5E4FF8 Q26778675-C1DB989E-2E84-4A91-B1EB-5DFF6627F142 Q26782584-935BA090-39DC-4CE1-9C06-12C334B1E804 Q27027865-48F57135-A136-4023-AA36-715B8FFFACFC Q28240692-5A2C92A8-3EF6-461E-8F81-C2BE089E8621 Q28270514-2A71724D-667C-47EA-A1A4-E81470072D26 Q28372484-A422F17A-1D80-43DF-872E-07AD2E350B82 Q28485944-C71087FF-70D1-4CC1-85D9-956D229132D0 Q30417300-6D683617-5E80-4A37-B0B7-093EAA891E2D Q30453296-E02A2485-1718-48BB-A33E-2CCCC5046E6B Q31122593-C14FAFF0-12A3-4520-A646-095D5BE72048 Q31160308-0AF9C225-17F6-43ED-860C-B7D4FC98172B Q33318578-8F19820D-2687-4509-B058-58478DB108BA Q33416887-70535CD2-870E-4941-B5B8-224692F650F1 Q33480671-F596830B-2A5A-4053-9726-09CC58112C2E Q33560459-5633482A-207E-47A3-8F7B-05FCEC45E70B Q33561166-A4847588-1BC7-43A7-93B6-64864DFF1C14 Q33566957-B3CDD34D-071A-40A0-890A-9DF51D05B2B2 Q33593009-C3C24AB7-37C1-4A22-A9B3-C2E3707CA0F1 Q33593016-65A61AF3-9C9B-41F0-BD94-B284CEF21639 Q33646842-8D2B3F18-B56D-4AAE-8F5A-DC48DDFA539F Q33659361-EF86088F-71FC-4B16-B676-8A7FECB4C358 Q33766513-4106D3BD-7FB9-4EE5-9ECC-D4E7B9D4DAE3 Q33769821-8EBAEB20-253F-4FB1-A2AB-3B0887745E25 Q33796082-9B9F48B3-6614-403F-A913-4D90F2D31695 Q33883406-BCEDA8DD-765C-4784-94AC-2F2937C0D4F0 Q33900930-0A6B2993-B4B2-45B3-BB9A-A9F4BAA61AD8 Q33990934-AFE7EC8D-9830-4EF3-8377-605C4DB90234 Q34023749-69C8A2D2-7232-40B0-B742-D9B143FC5FCA Q34114644-1CB48D27-D61A-44A6-BE93-3CD358BFAF49 Q34193932-CA9D75F4-0808-43D2-8200-DBE4954C4C69 Q34203914-0670A49E-3FCE-43B6-A69E-DD7F370B6FFA Q34234217-F58075A6-5792-41DA-9B31-DE5585861588 Q34253719-57CE0950-5354-47DF-AC68-E1D2FCA38B8F Q34284263-F7EA5484-10B3-469E-9C31-1E3A1A105D93 Q34284284-5EB2DF0B-3FCE-4688-BC6E-41E96A23A394 Q34315684-B3A27DC3-C210-45EE-B26D-140D2C5EEA0A Q34328227-486988C9-91FF-469E-996C-CB7DDA109130

P2860

Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer.

http://www.wikidata.org/entity/Q34601123

description

2006 nî lūn-bûn

@nan

2006 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Estrogen-receptor status and o ...... h node-positive breast cancer.

@ast

Estrogen-receptor status and o ...... h node-positive breast cancer.

@en

Estrogen-receptor status and o ...... h node-positive breast cancer.

@nl

type

label

Estrogen-receptor status and o ...... h node-positive breast cancer.

@ast

Estrogen-receptor status and o ...... h node-positive breast cancer.

@en

Estrogen-receptor status and o ...... h node-positive breast cancer.

@nl

prefLabel

Estrogen-receptor status and o ...... h node-positive breast cancer.

@ast

Estrogen-receptor status and o ...... h node-positive breast cancer.

@en

Estrogen-receptor status and o ...... h node-positive breast cancer.

@nl

P1433

Q34601123-12C973C9-1E22-4DF2-AE65-6F88903EDDB4

P1476

Q34601123-61C16150-8C76-44C1-8EC6-583BA26E146D

P2093

Q34601123-0C16413C-C09F-4DB3-B174-4D0CE802DC06

Q34601123-39565593-65BC-457C-8175-2D4A7A81863F

Q34601123-5F23D7A1-1892-4D74-B047-90A17E8083BB

Q34601123-75233004-7C86-4E62-9E29-54A5A71BB0CD

Q34601123-8A81EC56-6DC9-4AC5-AB6C-6707DEBAA4E8

Q34601123-BE775198-2F30-49D2-8DE8-E30802C9C8EE

Q34601123-C1EA0D1C-E6B4-4D33-AAD5-D74966A4285F

Q34601123-C94D839F-4360-4038-A01D-49D7AC77CA99

Q34601123-F343F562-FCE2-44AD-A71C-A16FE8C7AF89

Q34601123-FCCACDD2-E05D-4DCA-954B-0A0CDB067B4A

P2860

Q34601123-0B9C37B3-FFD7-4F5B-B48B-1A3C69EC28DD

Q34601123-16AD952C-283F-41B1-90EE-DD74F4468952

Q34601123-1D6DC23D-00DA-4DD1-A498-3EBADC7B59C0

Q34601123-2F9E065B-E3C9-4ACE-890E-180795AB822E

Q34601123-33C2550D-EC48-4E1A-8ED7-52F1F8280C7D

Q34601123-3684DC34-9F07-4B7B-94E8-248AAA5ACE9F

Q34601123-3B655EF9-6A2A-479B-803B-B6227B7483D8

Q34601123-40B38958-B526-4795-A6EF-02A2C530CBFF

Q34601123-489A8C76-D7E5-4B56-9B70-75AA4A6BCBAE

Q34601123-4C164379-7953-4AFD-96D2-E2F981DF4031

P304

Q34601123-E3A0E213-C2C2-4771-AF5E-2C7EB01208E5

P31

Q34601123-4EBDB175-DA2C-4C54-BCD1-76A60E43F0ED

P356

Q34601123-DE997A72-56E7-4F5B-9AC2-B5F536FE488D

P407

Q34601123-49B92E93-8FC6-49A1-802C-A343077B266D

P433

Q34601123-AC0A42C4-930A-430B-9C4F-43C95DBDE2DA

P478

Q34601123-A9E10404-41DA-4961-8B50-48B751ECACEA

P50

Q34601123-514830DC-1185-4B30-B59F-317448E8D0A5

P577

Q34601123-D593779E-100B-4A04-856E-BDEA0956F140

P5875

Q34601123-6D9FC1C1-C620-4BA1-82B5-B733CDF1E9F9

P698

Q34601123-FD1AC12C-5988-459D-9091-A83223E22B62

P921

Q34601123-36658F04-9553-4155-9055-2F4CE7E0C073

Q34601123-AC373878-6CFA-489B-A8AE-158F30BC6BE6

P932

Q34601123-21D0EEB3-09B8-4097-8EE5-9A9B6BB2B223

P356

JAMA.295.14.1658

P1433

Journal of the American Medical Association

P1476

Estrogen-receptor status and o ...... h node-positive breast cancer.

@en

P2093

Clifford Hudis

http://www.w3.org/2001/XMLSchema#string

Constance Cirrincione

http://www.w3.org/2001/XMLSchema#string

Daniel R Budman

http://www.w3.org/2001/XMLSchema#string

Donald A Berry

http://www.w3.org/2001/XMLSchema#string

Edith A Perez

http://www.w3.org/2001/XMLSchema#string

Eric P Winer

http://www.w3.org/2001/XMLSchema#string

Hyman B Muss

http://www.w3.org/2001/XMLSchema#string

I Craig Henderson

http://www.w3.org/2001/XMLSchema#string

Lori J Goldstein

http://www.w3.org/2001/XMLSchema#string

Marc L Citron

http://www.w3.org/2001/XMLSchema#string

P2860

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

Subgroup analysis and other (mis)uses of baseline data in clinical trials.

Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer.

Ongoing adjuvant trials with trastuzumab in breast cancer.

Orphan comparisons and indirect meta-analysis: a case study on antidepressant efficacy in dysthymia comparing tricyclic antidepressants, selective serotonin reuptake inhibitors, and monoamine oxidase inhibitors by using general linear models.

Effect of screening and adjuvant therapy on mortality from breast cancer.

Comparison of the dose-response relationships of 2 lipid-lowering agents: a Bayesian meta-analysis.

Efficacy and safety of trastuzumab.

P304

1658-1667

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1001/JAMA.295.14.1658

http://www.w3.org/2001/XMLSchema#string

P407

P433

14

http://www.w3.org/2001/XMLSchema#string

P478

295

http://www.w3.org/2001/XMLSchema#string

P50

P577

2006-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7171249

http://www.w3.org/2001/XMLSchema#string

P698

16609087

http://www.w3.org/2001/XMLSchema#string

P921

P932

1459540

http://www.w3.org/2001/XMLSchema#string